Figure 2

Kaplan-Meier curve for (A) progression-free survival (PFS) and (B) overall survival (OS) of intention-to-treat non-small cell lung cancer (NSCLC) patients receiving intercalating and maintenance use of gefitinib plus chemotherapy vs. chemotherapy alone. GC = gemcitabine; HR = hazards ratio.